Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains

High interpatient variability in the pharmacokinetics (PK) of nanomedicines has been reported. Heterogeneous recognition and clearance pathways of nanoparticles, such as the mononuclear phagocyte system (MPS), may contribute to the variable disposition of nanomedicines. However, molecular mechanisms for high interindividual PK variability of nanomedicines remain poorly understood. In this study, we identified a correlation between strain-specific differences in PLD clearance and genetic variation within Gulp1 encoding PTB domain containing engulfment adapter 1 protein (GULP1) in 23 inbred mouse strains. Our findings suggest that genetic variants in Gulp1 may provide important information on individualizing nanoparticle-based therapies in the human population.302